Merck Announces FDA Orphan Drug Designation for BifunctionalImmunotherapy M7824 in Biliary Tract Cancer
Darmstadt, Germany (ots/PRNewswire) - The information contained is
not intended for distribution in the USA, Canada or the UK
* FDA grants M7824, an investigational bifunctional immunotherapy,
orphan drug designation in biliary tract cancer
* First regulatory designation for M7824 following recent
presentation of first clinical data in BTC
* BTC is a group of rare, aggressive gastrointestinal cancers
associated with limited treatment options and poor outcomes
Merck, a leading science and!-->…